News|Articles|April 2, 2021

Pharmaceutical Technology

  • Pharmaceutical Technology-04-02-2021
  • Volume 45
  • Issue 4

Reducing Uncertainty of an Analytical Method through Efficient Use of Replication

A well-chosen replication strategy can effectively reduce the uncertainty for an analytical method, enabling appropriate decisions regarding pharmaceutical quality.

For a robustly developed analytical method, a well-chosen replication strategy can effectively reduce the uncertainty. A statistically sound approach involves replicating the factors associated with large amounts of variation followed by an appropriate analysis. The amount of reduction in uncertainty needed is informed by the precision requirements of the analytical target profile (ATP), ensuring that risks of making inappropriate quality decisions are minimized.

In this article, the authors describe two case studies: the use of a high-performance liquid chromatography separation method for a small-molecule API and a bioassay for a biopharmaceutical or vaccine.

Read this article as a PDF.

About the authors

Phil Borman, DSc, is senior fellow and director of product quality, GlaxoSmithKline; Timothy Schofield is owner and consultant, CMC Sciences, LLC; and David Lansky, PhD, is president, Precision Bioassay, Inc.

Article Details

Pharmaceutical Technology
Vol. 45, No. 4
April 2021
Pages: 46–56

Citation

When referring to this article, please cite it as P. Borman, T. Schofield, and D. Lansky, “Reducing Uncertainty of an Analytical Method through Efficient Use of Replication,” Pharmaceutical Technology 45 (4) 2021.


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.